Archive for the ‘Gene Therapy Research’ Category

Lecture 9: Seeing the World in Color
What is color? Dr. Christof Koch explores how color is "made" in the brain and variations of color perception including trichromacy, color blindness in men, tetrachromatic vision in women, and genetic engineering of color perception. This full-length, undergraduate-level lecture is the ninth of a 12-part series entitled Vision Coding 101, produced by the Allen Institute for Brain Science as an educational resource for the community.From:AllenInstituteViews:10 0ratingsTime:01:11:09More inEducation

See original here:
Lecture 9: Seeing the World in Color - Video

DNA Technology Part 1
Introduction to genetic engineering. Restriction enzymesFrom:Kirk KennedyViews:0 0ratingsTime:11:02More inEducation

Read more here:
DNA Technology Part 1 - Video

Alan Watt Blurb - A Good Example Of Predictive Programming - April 11, 2007
Alan Watt Videos playlist - http://www.youtube.com This is Alan Watt #39;s blurb from April 11, 2007. mp3 - http://www.cuttingthroughthematrix.com transcript - http://www.cuttingthroughthematrix.com April 11, 2007 Alan Watt Blurb (ie Educational Talk) "A Good Example of Predictive Programming" Topics discussed: New "Posh" Bound Books, Red-Flagged Emails - Impossible to Answer All, "Corporations Will Push Humans into Alternate Realities", World Corporations - Proctor and Gamble - Bottled Infant Formulas - Sterilized Jars with Synthetic Form of Estrogen - Charles Galton Darwin - Effeminization, Public Programming, Rand Corp., Ford Foundation - Carnegie - Rockefeller - IFTF - Futurist Think-Tanks, Entertainment - Fascinated to Death, Communist Writings - Destruction of Family Unit - Separation of Male and Female, State Care-Takers, Relation of Life and Death, "Old Folks" Homes, Increasing Indoctrination with Each Generation, Welfare State, Multi-Millionaire Lawyer-Politicians, Authorized Candidates, Genetic Engineering, Financing Genetic Research - Purpose-Made Humans - Huxley #39;s "Brave New World", Bio-Ethics Committees, Splicing Human Genes into Animals, Brain-Chipping, UN - UNESCO - World Culture - Brainwashing - Future Bureaucrats, "Utopia", Video Games - Sports - Heroes, Use of Repetitive Slogans, Gullibility of the Young - Soldiers for War - No Thought of Death, Virtue - Virtual - Promises of Better Housing and Living - Utopia, World War I and II, HG Wells - War Propaganda, United Europe, Alan #39;s ...From:1stageofawarenessViews:2 0ratingsTime:50:31More inEducation

Read more:
Alan Watt Blurb - A Good Example Of Predictive Programming - April 11, 2007 - Video

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/xhrqtk/molecular) has announced the addition of Elsevier Science and Technology's new book "Molecular Medicine. Edition No. 4" to their offering.

Molecular Medicine is the application of genetic or DNA-based knowledge to the modern practice of medicine. Molecular Medicine, 4e, provides contemporary insights into how the genetic revolution is influencing medical thinking and practice. The new edition includes recent changes in personalized medicine, new growth in omics and direct-to-consumer DNA testing, while focusing on advances in the Human Genomeproject and implications of the advances in clinical medicine. Graduate students, researchers, clinicians and allied health professionals will appreciate the background history and clinical application of up-to-date molecular advances.

Key Features

- Extensively revised to incorporate the results of the Human Genome Project, it provides the latest developmentsin molecular medicine

- The only book in Molecular Medicine to reach its fourth edition

- Identifies current practice as well as future developments

- Presents extensive tables, well presented figures and resources for further understanding

Topics Covered:

Dedication and Acknowledgements

Follow this link:
Research and Markets: Molecular Medicine. Edition No. 4

Peter Blume-Jensen from Metamark Genetics
Peter Blume-Jensen, Chief Scientific Officer of Metamark Genetics, sits down with Slone Partners at the Personalized Medicine Conference in Boston to discuss their novel platform Prognosis Determinant. "Through its proprietary Prognosis Determinant trade; Discovery Platform, Metamark has identified and validated functionally active genetic determinants of metastasis that are critical to the progression of a broad spectrum of tumor types." - http://www.metamarkgenetics.com The 8th Annual Personalized Medicine Conference was hosted at Harvard Medical School by Partners Healthcare.From:SlonePartnersMediaViews:44 0ratingsTime:02:57More inScience Technology

See the original post:
Peter Blume-Jensen from Metamark Genetics - Video

Peter Blume-Jensen of Metamark Genetics on Prognosis Determinants
Peter Blume-Jensen, Chief Scientific Officer of Metamark Genetics, sits down with Slone Partners at the Personalized Medicine Conference in Boston to discuss their novel platform Prognosis Determinant. "Through its proprietary Prognosis Determinant trade; Discovery Platform, Metamark has identified and validated functionally active genetic determinants of metastasis that are critical to the progression of a broad spectrum of tumor types." - http://www.metamarkgenetics.com The 8th Annual Personalized Medicine Conference was hosted at Harvard Medical School by Partners Healthcare.From:SlonePartnersMediaViews:10 0ratingsTime:02:41More inScience Technology

Go here to see the original:
Peter Blume-Jensen of Metamark Genetics on Prognosis Determinants - Video

Supreme Court to Decide Whether or Not Human Genes are Patentable mdash;Antoinette Konski
In a Supreme Court ruling that may have major consequences for the near future of medical research, the Court will soon determine whether or not human genes are patentable. At the heart of the case: Myriad Genetics has claims on patents related to two genes linked to breast and ovarian cancer. Joining me today to discuss this case is Antoinette Konski of Foley Lardner mdash;she #39;s been tracking and providing commentary on this case through the Personalized Medicine Bulletin.From:TheLexBlogNetworkViews:0 0ratingsTime:04:58More inScience Technology

See the article here:
Supreme Court to Decide Whether or Not Human Genes are Patentable—Antoinette Konski - Video

Analytic Issues Associated with Rare Variant Testing (2012)
The Primer on Medical and Population Genetics is a series of informal weekly discussions of basic genetics topics that relate to human populations and disease. Experts from across the Broad Institute community give in-depth introductions to the basic principles of complex trait genetics, including human genetic variation, genotyping, DNA sequencing methods, statistics, data analysis, and more. Videos of these sessions are made freely available for viewing here and are geared toward a wide audience that includes research technicians, graduate students, postdoctoral fellows and established investigators just entering the field. For more information, please visit: -Program in Medical Population Genetics (www.broadinstitute.org -Primer videos (www.broadinstitute.orgFrom:broadinstituteViews:1 0ratingsTime:56:48More inScience Technology

Visit link:
Analytic Issues Associated with Rare Variant Testing (2012) - Video

Science Human Origins: How accurate are current models used in population genetics?
Ann Gauger is Senior Research Scientist at Biologic Institute. She received her Ph.D. in developmental biology from the University of Washington and was a post-doctoral fellow at Harvard University. Science Human Origins (www.discoveryinstitutepress.com the provocative new book from Discovery Institute Press, boldly addresses some of the most popular evolutionary arguments pertaining to controversial claims that humans and apes are related through common ancestry. In Science Human Origins three scientists challenge the claim that undirected natural selection is capable of building a human being. The authors critically assess fossil and genetic evidence that human beings share a common ancestor with apes, and debunk recent claims that the human race could not have started from an original couple.From:DiscoveryInstituteViews:18 0ratingsTime:02:51More inScience Technology

See the original post here:
Science

Dvorcast Event Watch: 12/17 - 12/23
Check out these great events coming up this week at Dvor.com NOW! http://www.dvor.com Events in this week #39;s Dvorcast include Monday, 12/17 GunVault Radio Vault Carson Mini Aura Digital Night Vision Monocular Weeklong Deal http://www.youtube.com Tuesday, 12/18 Range Ready Gear Best Bets Under $100 Wednesday, 12/19 Reflex Sights Tipton Best Gun Vise Thursday, 12/20 Magpul Event Insight Technology HX Flashlights Friday, 12/21 Laser Genetics Event End of the World 1 Day Sale Saturday, 12/22 Mil Dot Riflescopes Blackhawk Knives Sunday, 12/23 Bring on a Maxpedition Crimson Trace DEMO Units Find all these events at http:/www.dvor.com!From:dvorViews:2 0ratingsTime:01:36More inHowto Style

Original post:
Dvorcast Event Watch: 12/17 - 12/23 - Video

Charlie Wolf - Cameron in Dundee - Genetics
Subscribe to my channel for regular brand new clips. All copyrights are held by their respective owners. Please check this link out. tiny.ccFrom:dpro73Views:0 0ratingsTime:06:46More inEntertainment

Read more:
Charlie Wolf - Cameron in Dundee - Genetics - Video

FISH to visualize genetic abnormalities characteristic of pancreatic cancer
Dr. Gordon DeWald, professor emeritus in laboratory medicine and laboratory genetics at Mayo Clinic, provides an overview of his study on the use of FISH (Fluorescence In Situ Hybridization) to visualize genetic abnormalities characteristic of pancreatic cancer. Available at: tinyurl.comFrom:Mayo ProceedingsViews:0 0ratingsTime:06:47More inScience Technology

Visit link:
FISH to visualize genetic abnormalities characteristic of pancreatic cancer - Video

Planetside 2 - Terran Republic - The Battle for Apex Genetics
VICTORY IS OUR TRADITIONFrom:newbiebokaViews:0 0ratingsTime:05:27More inGaming

Read more here:
Planetside 2 - Terran Republic - The Battle for Apex Genetics - Video

ATLANTA--(BUSINESS WIRE)--

Seattle Genetics, Inc. (SGEN) today announced results from a phase I clinical trial of ADCETRIS (brentuximab vedotin) in combination with chemotherapy for the treatment of newly diagnosed mature T-cell lymphoma (MTCL) patients, including patients with systemic anaplastic large cell lymphoma (sALCL). The data were presented at the 54th American Society of Hematology (ASH) Annual Meeting and Exposition being held December 8-11, 2012 in Atlanta, GA. ADCETRIS is an antibody-drug conjugate (ADC) directed to CD30. ADCETRIS is not currently approved for use in the front-line treatment of MTCL.

In the phase I trial, newly diagnosed patients received six cycles of ADCETRIS every three weeks in combination with cyclophosphamide, doxorubicin and prednisone (CHP). This regimen removes vincristine (Oncovin) from CHOP, the standard treatment in this setting. Patients who achieved at least a partial remission after completing six cycles of combination therapy were eligible to receive continued single-agent ADCETRIS for up to ten additional 3-week cycles. The primary endpoints of the trial included defining maximum tolerated dose of ADCETRIS in combination with CHP and evaluating safety. The secondary endpoints were investigator assessment of response, progression-free survival and overall survival.

After completing combination therapy, 26 of 26 patients (100 percent) treated with ADCETRIS plus CHP had an objective response, including 23 patients (88 percent) with a complete remission. All 23 patients who achieved a complete remission demonstrated normalized glucose uptake by PET (positron emission tomography) evaluation.

The standard front-line regimen for patients with mature T-cell lymphomas is a combination chemotherapy regimen, CHOP, that has demonstrated complete remission rates of 39 to 53 percent, with a 5-year overall survival rate of less than 50 percent, said Michelle Fanale, M.D., Associate Professor in the Department of Lymphoma/Myeloma, Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center. There is significant need to advance the treatment paradigm for newly diagnosed patients with these aggressive types of lymphoma. Data from this trial support further evaluation of ADCETRIS in the front-line treatment of patients with mature T-cell lymphomas.

Brentuximab Vedotin Administered Concurrently with Multi-Agent Chemotherapy as Front-line Treatment of ALCL and Other CD30-Positive Mature T-Cell and NK-Cell Lymphomas (Abstract #60)

Data were reported from 26 previously untreated patients who received the combination regimen of ADCETRIS plus CHP. Nineteen patients had sALCL, and seven patients had a diagnosis of another mature T- or NK-cell lymphoma. The median age of patients was 56 years. Key findings, which were highlighted in an oral presentation by Dr. Fanale, include:

These data provide strong rationale for our planned phase III clinical trial to evaluate ADCETRIS plus CHP compared to CHOP in front-line patients with mature T-cell lymphomas, said Clay B. Siegall, Ph.D., President and Chief Executive Officer at Seattle Genetics. We are encouraged by the potential to introduce ADCETRIS into a novel regimen for these patients, with a goal of redefining front-line therapy from the standard therapeutic approach that has not seen an advance in decades.

A phase III clinical trial of ADCETRIS in CD30-positive MTCL patients is planned to compare progression-free survival in patients receiving ADCETRIS in combination with CHP (A+CHP) to patients receiving CHOP alone. The trial is expected to begin by late 2012 or early 2013.

About ADCETRIS

Link:
Seattle Genetics Reports Data from Phase I Trial of ADCETRIS® (Brentuximab Vedotin) in Front-line Mature T-Cell ...

Gene Therapy Part 2 Mr. Bell Second Period
Marisa, Daniel, CiaraFrom:bellshonorsbioViews:2 0ratingsTime:02:31More inEducation

Read the original here:
Gene Therapy Part 2 Mr. Bell Second Period - Video

BIOTECH GENE THERAPY
biotechFrom:JwalkProductions222Views:2 0ratingsTime:03:46More inMusic

See more here:
BIOTECH GENE THERAPY - Video

Swimmers Make Waves Against Cancer
Watch more and discuss: stamford.itsrelevant.com Swim Across America #39;s Stamford-Greenwich swim enjoyed its sixth outing on Saturday, raising $400000 that will fund cancer gene therapy research at the Alliance for Cancer Gene Therapy in Stamford. Produced By: Mike PealFrom:irstamfordViews:0 0ratingsTime:01:44More inNews Politics

Go here to read the rest:
Swimmers Make Waves Against Cancer - Video

Producing Viral Vectors for Clinical Trials With On-Site Clinical Manufacturing Facility
Viral gene therapy is being tested as treatment for numerous diseases, including cancer, cystic fibrosis, heart disease, muscle diseases, diabetes and neurodegenerative disease like Parkinson #39;s. While gene therapy is still available only as part of a clinical trial, scientists, clinicians and families hold hope that it will eventually become a fundamental part of modern medicine and provide treatment for the currently untreatable. Modified viruses used to deliver genetic material into cells, known as viral vectors, have become the go-to delivery capsule in gene therapy. Investigators use viral vectors to efficiently target certain cells and deliver genetic material into the cell nucleus where native genes reside. Nationwide Children #39;s has a unique facility that specializes in creating these viral vectors - a rare, incredibly beneficial asset to our Research Institute - called the Clinical Manufacturing Cleanroom Facility. So far, the Cleanroom Facility has produced several vectors for use in investigational new drug studies, and products for phase I clinical trials for the congenital blindness disorder, choroideremia, muscular dystrophy and inclusion body myositis. Additional trials focused on spinal muscular atrophy and Duchenne and limb girdle muscular dystrophies are in the works. Having this facility on-site allows for expedited clinical trials at a much more affordable price, which all comes back to being able to offer the best possible care for all of our patients ...From:NationwideChildrensViews:5 0ratingsTime:01:33More inNonprofits Activism

Read the rest here:
Producing Viral Vectors for Clinical Trials With On-Site Clinical Manufacturing Facility - Video

Gene Therapy- Mr. Shackelford 4th period
My First ProjectFrom:elitecheeer13Views:2 0ratingsTime:01:51More inScience Technology

Read more:
Gene Therapy- Mr. Shackelford 4th period - Video

AXA y Ponle Freno, promoting road safety ® AXA Vídeo Oficial
Fun running race #39;Ponle Freno #39; 4th edition took place in Madrid on November 25. It was the first action since AXA entered into strategic partnership with Ponle Freno social platform. And because of that, we did our best to make it a resounding success. The outcome couldn #39;t be better: bull; Record number of participants, with a large number of AXA employees and their relatives running bull; Fundraising record. Money will support a research project on stem cell therapy for spinal cord injury at Puerta de Hierro Hospital (Madrid). bull; Launching of new app ( #39;Corremos Juntos #39;) that allowed thousands of people to participate in the race all over the world for the first time. bull; AXA employees showed their engagement and commitment to the project, with hundreds running in Madrid and also in some other cities in Spain thanks to the app. In short, an unforgettable day for all people worried about road safety, as shown in the video above. axa.es "Like Music" by Admiral Bob (feat. snowflake) ccmixter.org is licensed under a Creative Commons license: creativecommons.orgFrom:AXASEGUROSESViews:33 0ratingsTime:03:21More inNonprofits Activism

Read the original:
AXA y Ponle Freno, promoting road safety ® AXA Vídeo Oficial - Video

Randall avoids knee replacement surgery after adult stem cell therapy by Dr Harry Adelson
Randall describes his experience with adult stem cell therapy by Dr Harry Adelson on his arthritic knee and ankleFrom:Harry AdelsonViews:0 0ratingsTime:01:08More inScience Technology

The rest is here:
Randall avoids knee replacement surgery after adult stem cell therapy by Dr Harry Adelson - Video

Benefits of Live Cell Therapy | Live Cell Therapy For Cellular Regeneration
stemcellmalaysia.com Live cell therapy renders more than beauty and anti-aging. Live cell therapy regenerates and renews the cells, tissues, organs and glands of our body. The regeneration and renewal within result in the outward expression of youthfulness and aging reversal. The processes of internal regeneration and renewal invariably result in disease treatment and recovery from illnesses looming within the body. For more information on live cell therapy benefits, please visit Stem Cell Malaysia at stemcellmalaysia.comFrom:stemcells2012Views:0 1ratingsTime:09:01More inScience Technology

Read this article:
Benefits of Live Cell Therapy | Live Cell Therapy For Cellular Regeneration - Video

LONDON, ONTARIO--(Marketwire - Dec 13, 2012) - Critical Outcome Technologies Inc. (COTI) (TSX VENTURE:COT) released important new test results today proving that COTI-2, the company''s lead oncology candidate, stops cancer cells from replicating by correcting the effects of specific genetic errors affecting the p53 gene. COTI''s previous research had identified a strong statistical relationship between the presence of several p53 mutations and COTI-2''s in-vitro effectiveness in cancer cell lines with these mutations.

"Our experiments showed that COTI-2, at a low dose, restored the normal protein configuration of the R175H p53 gene mutation and did not affect normal p53 protein," said Dr. Wayne Danter, COTI''s President and CEO. "The R175H variant is found in many human cancers with additional strong statistical evidence suggesting that COTI-2 is highly effective in at least two other p53 ''HotSpot'' mutations found in about 20% of all human cancers. Additional experiments are planned to confirm the effect of COTI-2 on these other common p53 mutations (R248W and R273H)."

This new information represents an important advance in the understanding of COTI-2''s specific gene mutation mechanism of action with the results extending the test outcomes generated by Dr. Yu et al from the University of New Jersey as published in the May 2012 edition of the journal, Cancer Cell.

In the experiments:

"With this and other exciting new mechanism of action data we have decided to engage Destum Partners, a boutique advisory firm, in order to help bring new potential partners into dialogue and meet our timelines in securing a partnership for COTI-2. As such, all business development related inquiries should be directed to Destum Partners Inc." concluded Dr. Danter.

About Critical Outcome Technologies Inc.

COTI is a leading-edge company specializing in accelerating the discovery of small molecules thus enabling these new drugs to be brought to market in a more cost effective, efficient and timely manner. COTI''S proprietary artificial intelligence system, CHEMSAS, utilizes a series of predictive computer models to identify compounds with high probability of being successfully incorporated in disease- specific drug discovery, as well as subsequent optimization and preclinical development. These compounds are targeted for a variety of diseases, particularly those for which current treatments are either lacking or ineffective.

For more information, visit http://www.criticaloutcome.com.

About Destum Partners, Inc.

Destum is a boutique consulting and advisory firm designed to effectively meet the demands of the Biopharmaceutical and Life Sciences industries. Destum serves an exclusive clientele dedicated to pushing the boundaries of technology innovation to improve the quality of life of humanity. Our Clients range from multinational pharmaceutical corporations to private early stage biotechnology companies throughout the globe. Destum''s advisory services include buy and sell side advisory, M&A, licensing, and research collaborations. Destum''s consulting services include Product and Market Assessments and Asset Valuations which are powered by a cross functional team that brings scientific, market, commercial, and financial expertise together to provide insightful and actionable guidance.

Continued here:
COTI-2 Found to Correct Specific p53 Gene Mutation in Human Ovarian Cancer Cells

Genetic Engineering Overview (Group 1, Period 2)
From:bellshonorsbioViews:0 0ratingsTime:05:44More inEducation

The rest is here:
Genetic Engineering Overview (Group 1, Period 2) - Video

Dan Becker, The Pillars of Personhood, Part 1, IRSC, Unedited
Dan Becker, The Pillars of Personhood, Part 1, at IRSC, Unedited, Personhood, Personhood USA, Personhood FL, ProLife, Abortion, Euthanasia, Cloning, Fetal Tissue Research, Human Animal Hybrids, Assisted Suicide, PGD, Pre-implantation Genetic Diagnosis, Eugenics, Disabled, Genocide, H+, Homo Perfectus, Transhumanism, Ectogenesis, Transgenetics, Nanotechnology, Cyborgology, Artificial Intelligence, Genoism, Genetic Engineering, EmbryosFrom:Personhood FloridaViews:0 0ratingsTime:49:21More inNews Politics

Read this article:
Dan Becker, The Pillars of Personhood, Part 1, IRSC, Unedited - Video